Physician profile
Lan T Le
NPI 1417166240
$4,583.59
in general payments reported to CMS, 2019-2025
25 companies · $537 in 2025
The $537 reported for 2025 was more than what 80% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $566 · 2021: $470 · 2022: $646 · 2023: $865 · 2024: $958 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,129.63 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $1,027.62 | 2021-2025 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $551.74 | 2019-2025 | Dysport |
| Merz North America, INC. | $432.05 | 2019-2020 | |
| Allergan, INC. | $245.13 | 2019-2022 | |
| Saol Therapeutics INC. | $199.35 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $159.43 | 2019-2022 | |
| Medtronic USA, INC. | $152.57 | 2019-2020 | |
| Piramal Critical Care | $141.51 | 2022-2025 | |
| Medtronic, INC. | $131.39 | 2021-2025 | Synchromedii, Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $64.57 | 2023 | Lyvispah |
| Sanofi Pasteur INC. | $52.79 | 2023-2024 | |
| Lundbeck LLC | $45.06 | 2024-2025 | Vyepti |
| Microtransponder, INC. | $39.18 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $28.48 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $26.76 | 2022 | |
| Electronic Waveform Lab, INC. | $19.51 | 2024 | |
| Si-Bone, INC. | $19.46 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.14 | 2023 | Nuedexta |
| Pacira Therapeutics, INC. | $17.64 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.43 | 2019 | |
| Neuros Medical, INC. | $16.66 | 2025 | Altius |
| Boston Scientific Corporation | $16.31 | 2021 | |
| Ossur Americas, INC. | $15.99 | 2025 | |
| Bioventus LLC | $14.19 | 2024 | L300 Go System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.